Background and Objective: Histone Deacetylases (HDACs) are important therapeutic targets for
many types of human cancers. A derivative of valproic acid, N-(2-hydroxyphenyl)-2-propylpentanamide (HOAAVPA),
has antiproliferative properties on some cancer cell lines and inhibits the HDAC1 isoform.
Materials and Methods: In this work, HO-AAVPA was tested as an antiproliferative agent in U87-MG (human
glioblastoma) and U-2 OS cells (human osteosarcoma), which are types of cancer that are difficult to treat, and
its antiangiogenic properties were explored.
Results: HO-AAVPA had antiproliferative effects at 48h with an IC50=0.655mM in U87-MG cells and an
IC50=0.453mM in U-2 OS cells. Additionally, in the colony formation assay, HO-AAVPA decreased the number
of colonies by approximately 99% in both cell lines and induced apoptosis by 31.3% in the U-2 OS cell line and
by 78.2% in the U87-MG cell line. Additionally, HO-AAVPA reduced the number of vessels in Chorioallantoic
Membranes (CAMs) by approximately 67.74% and IL-6 levels in both cell lines suggesting that the biochemical
mechanism on cancer cell of HO-AAVPA is different compared to VPA.
Conclusion: HO-AAVPA has antiproliferative effects on glioblastoma and osteosarcoma and antiangiogenic